The Novartis Access portfolio will be rolled out first in Kenya, Ethiopia and
Vietnam, but Novartis ultimately intends to offer the programme in as many as
30 countries, depending on uptake.
The Swiss
drug giant said it is also looking to partner with governments, NGOs and other
public-sector organisations to strengthen healthcare systems, with areas of
potential collaboration including raising diseases awareness, training
healthcare professionals, and strengthening medicine distribution systems.
Around 28
million people die from chronic diseases in low- and middle-income countries
every year, accounting for 75% of such deaths globally. Novartis said it
believes its unique approach to improving access to potentially life-saving
medicines will be commercially Novartis rolls out access programme for 15
medicines
Novartis
has launched an access programme under which 15 of its medicines will be
offered to healthcare providers in low- and low-middle-income countries for
just $1 per drug per month.
The
treatments on offer - both patented and generic - are all geared towards
treating chronic diseases such as diabetes, respiratory illnesses, and breast
cancer, to help reign in their growing spread in areas of the world with
limited sustainable over the long term, enabling it to provide continuous
support in these regions. (Ver)
Ver también:
Is The U.S. Trying To Thwart Poor Countries From Gaining Access To Medicines?
No hay comentarios:
Publicar un comentario